EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Inflammatory Signatures in VEXAS Syndrome, Myelodysplasia Cutis, and Sweet Syndrome

Chloé Grolleau, Maxime Battistella, Eve Zakine, Thomas Poisot, Florence Cordoliani, Thibault Mahevas, Marie Jachiet, Adèle de Masson, Arsène Mekinian, Benjamin Terrier, Sophie Georgin Lavialle, Pierre Fenaux und 11 weitere

JAMA Dermatology · 2025

DOI: 10.1001/jamadermatol.2025.0034 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JAMA Dermatology, 2025. Verfasst von Chloé Grolleau und 22 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Saint Louis Hospital, Paris, France. Hauptthemen laut MEDLINE: Sweet Syndrome, Myelodysplastic Syndromes, Genetic Diseases, X-Linked. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a monogenic disease caused by UBA1 somatic variants in hematopoietic progenitor cells, mostly involving adult men. It is associated with inflammatory-related symptoms, frequently involving the skin and hematological disorders. Recently described myelodysplasia cutis (MDS-cutis) is a cutaneous manifestation of myelodysplasia in which clonal myelodysplastic cells infiltrate the skin. In both cases, skin lesions are driven by the infiltration of clonal mutated myeloid cells and may clinically and histologically mimic Sweet syndrome (SS), a neutrophilic skin disease.

Objective

To decipher the underlying mechanisms driving these 3 myeloid-related skin diseases (ie, VEXAS, MDS-cutis, and SS) compared with leukemia cutis (LC), a neoplastic blastic myeloid-related skin condition, and healthy control skin samples. Design, Setting, and Participants This multicenter translational study on formaldehyde-fixed paraffin-embedded lesional skin samples of VEXAS syndrome, MDS-cutis, idiopathic SS, LC, and healthy controls using bulk RNA sequencing analyses was conducted in France. Patients included had cutaneous lesions of VEXAS syndrome, MDS-cutis, idiopathic SS, or LC. The data were analyzed from June 2023 to March 2024. Main Outcomes and Measures Differentially expressed genes between conditions were studied. These genes were used to characterize the enrichment in activated inflammatory pathways in each condition using Gene Set Enrichment Analysis and Ingenuity Pathway Analysis.

Results

Twenty patients with skin conditions (median [range] age, 67 [43-88] years; 10 [50%] men) were included. Six had cutaneous lesions of VEXAS syndrome, 4 had MDS-cutis, 5 had idiopathic SS, and 5 had LC. They were compared with 5 healthy control skin samples. Bulk RNA sequencing analysis reveals that MDS-cutis and VEXAS syndrome lesions display closely related transcriptomic profiles, highly imprinted by cytokine responses, interferon signatures, and activation of the apoptosis pathway. A shared inflammatory environment between MDS-cutis, VEXAS syndrome, and idiopathic SS was observed, mostly relying on a type 1 immune response led by type 1 and 2 interferons, along with the activation of tumor necrosis factor and interleukin (IL)–1β pathways. Conversely, LC showed an isolated transcriptomic profile mainly enriched in cell cycle pathways. Conclusions and Relevance The findings of this translational study highlight a common inflammatory pattern shared between VEXAS syndrome, MDS-cutis, and refractory idiopathic SS skin samples. This suggests the potential therapeutic targeting of interferon pathways in patients affected with refractory nonblastic myeloid-related skin diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sweet SyndromeMyelodysplastic SyndromesGenetic Diseases, X-LinkedHumansMaleFemaleMiddle AgedSkinAgedUbiquitin-Activating EnzymesAdultDiagnosis, DifferentialSkin Diseases, Genetic

Substanzen

Ubiquitin-Activating EnzymesUBA1 protein, human

Autor:innen und Institutionen

  • Dermatology Department, Saint Louis Hospital, Paris, France.
  • Saint-Louis Research Institute, INSERM U976-HIPI Unit, University of Paris, Paris, France.
  • Pathology Department, Hôpital Saint Louis, AP-HP, Paris, France.
  • Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Centre Hospitalo-Universitaire Saint-Antoine, Service de Médecine Interne et Inflammation-Immunopathology-Biotherapy Department (DMU i3), Paris, France.
  • National Referral Center for Rare Systemic Autoimmune Diseases, Université Paris Descartes, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.
  • AP-HP, Hôpital Tenon, Sorbonne Université, Service de Médecine Interne, Centre de Référence des Maladies Auto-Inflammatoires et des Amyloses d'Origine Inflammatoire (CEREMAIA); Hôpital Trousseau, Université Pierre-et-Ma…

Zitieren

APA

Grolleau, C., Battistella, M., Zakine, E., Poisot, T., Cordoliani, F., Mahevas, T., Jachiet, M., de Masson, A., Mekinian, A., Terrier, B., Lavialle, S. G., Fenaux, P., Adès, L., Zhao, L. P., Serror, K., Duchmann, M., Clappier, E., Onifarasoaniaina, R., Le Buanec, H., …, & FRENVEX Group (2025). Inflammatory Signatures in VEXAS Syndrome, Myelodysplasia Cutis, and Sweet Syndrome. JAMA Dermatology. https://doi.org/10.1001/jamadermatol.2025.0034

Vancouver

Grolleau C, Battistella M, Zakine E, Poisot T, Cordoliani F, Mahevas T, et al. Inflammatory Signatures in VEXAS Syndrome, Myelodysplasia Cutis, and Sweet Syndrome. JAMA Dermatology. 2025. doi:10.1001/jamadermatol.2025.0034

BibTeX
@article{Grolleau2025,
  author = {Grolleau, Chloé and Battistella, Maxime and Zakine, Eve and Poisot, Thomas and Cordoliani, Florence and Mahevas, Thibault and Jachiet, Marie and de Masson, Adèle and Mekinian, Arsène and Terrier, Benjamin and Lavialle, Sophie Georgin and Fenaux, Pierre and Adès, Lionel and Zhao, Lin-Pierre and Serror, Kevin and Duchmann, Matthieu and Clappier, Emmanuelle and Onifarasoaniaina, Rachel and Le Buanec, Hélène and Moguelet, Philippe and Bouaziz, Jean-David and Chasset, Francois and FRENVEX Group, FRENVEX Group},
  title = {Inflammatory Signatures in VEXAS Syndrome, Myelodysplasia Cutis, and Sweet Syndrome},
  journal = {JAMA Dermatology},
  year = {2025},
  doi = {10.1001/jamadermatol.2025.0034}
}
Kostenlos starten →